Rossari Biotech Ltd - Stock Valuation and Financial Performance

BSE: 543213 | NSE: ROSSARI | Chemicals | Small Cap

Rossari Biotech Share Price

618.10 -8.85 -1.41%
as on 04-Apr'25 10:14

DeciZen - make an informed investing decision on Rossari Biotech

Overall Rating
Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Rossari Biotech stock performance -

P/E Ratio (CD):
25.51
Market Cap:
3,471 Cr.
52-wk low:
568.1
52-wk high:
966

Is Rossari Biotech Ltd an attractive stock to invest in?

1. Is Rossari Biotech Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Rossari Biotech Ltd is a good quality company.

2. Is Rossari Biotech Ltd undervalued or overvalued?

The key valuation ratios of Rossari Biotech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Rossari Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Rossari Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Rossari Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Rossari Biotech Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 10.7%10.3%26.4%40.4%54.4%37.9%28.8%24.4%18.5%18.4%-
Value Creation
Index
-0.2-0.30.91.92.91.71.10.80.30.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1711792332925166007091,4831,6561,8311,973
Sales YoY Gr.-4.4%30.6%25%76.9%16.3%18.2%109.1%11.7%10.6%-
Adj EPS 0.80.73.35.99.512.615.316.318.322.624.6
YoY Gr.--7.9%364.3%81.9%60.1%33.1%21.8%6%12.9%23.1%-
BVPS (₹) 9.710.313.519.525.656.478.3145.7165.3189207.6
Adj Net
Profit
3.73.415.728.645.863.979.689.5101125136
Cash Flow from Ops. 8.125.77.223.671.256.847.829.415243.3-
Debt/CF from Ops. 5.40.93.10.90.11.200.30.52.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 30.1%28.8%37.2%10.6%
Adj EPS 45.8%19%13.8%23.1%
BVPS39.1%49.2%34.1%14.4%
Share Price - - -14.3% -14.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
7.7727.335.84231.122.914.711.812.712.4
Op. Profit
Mgn %
8.6710.415.315.117.517.411.91313.313.1
Net Profit
Mgn %
2.21.96.79.88.910.711.266.16.86.9
Debt to
Equity
0.90.50.30.200.2000.10.1-
Working Cap
Days
15313210710910714016313416618982
Cash Conv.
Cycle
8162424524132946687942

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 37.16%

Net Profit is growing at healthy rate in last 3 years 13.76%

Sales growth is good in last 4 quarters at 12.30%

Return on Equity has declined versus last 3 years average to 12.40%

Latest Financials - Rossari Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) 19.6 24.6
TTM Sales (₹ Cr.) 1,319 1,973
BVPS (₹.) 188.3 207.6
Reserves (₹ Cr.) 1,032 1,138
P/BV 3.33 3.02
PE 31.98 25.51
From the Market
52 Week Low / High (₹) 568.05 / 966.00
All Time Low / High (₹) 536.10 / 1620.60
Market Cap (₹ Cr.) 3,471
Equity (₹ Cr.) 11.1
Face Value (₹) 2
Industry PE 51.6

Quarterly Results

 Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %Mar'25 YoY Gr. Rt. %
Operating Income0 N/A0 N/A0 N/A0 N/A
Adj EPS (₹)N/A N/AN/A N/AN/A N/AN/A N/A
Net Profit Mgn %N/A N/AN/A N/AN/A N/AN/A N/A

Management X-Ray of Rossari Biotech:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:68.19%Institutions:21.21%Non-Institutions:10.6%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%10%20%30%40%50%60%70%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Rossari Biotech

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

Rossari Biotech: Initiating report - 24 Apr 2024

About the company

Rossari Biotech (Rossari) is a specialty-chemicals manufacturer which was established in 2003 as a partnership, between Mr. Edward Menezes and Mr. Sunil Chari. Rossari has built a strong base of more than 1000 customers across segments with the likes of Hindustan Unilever (Love & Care, Cif, Rin, Vim), Reliance (Enzo), Arvind, RaymondGokul Poultry Industries. Currently, they are distributing more than 4,250 products and delivering their services through 435 distributors in 28 states and 8 Union territories in India. Rossari also exports its products to more than 33 countries. 

Rossari operates 8 manufacturing facilities at Silvassa and Dahej in Gujarat, with a total production capacity of 354,100 MTPA. It has leveraged its 4 strategically placed R&D facilities, including a cutting-edge certified laboratory at the Mumbai IIT campus, to drive growth through smart chemistry and research. The company's R&D strength lies in its ability to swiftly deliver customized and cost-effective product solutions, encompassing synthesis, formulation, development, and technical services.

Rossari offers solutions in three main product categories:

  • Home, personal care, and performance chemicals (HPPC) - It manufactures chemicals which improve appearance, texture, performance, strength and process ability of end products for various industries. Example- It manufactures active agent for detergents. Rossari is involved in a wide range of activities, from supplying raw materials to developing complete products for other brands, allowing it to tap into various levels of the supply chain in the home care industry.
  • Textile specialty chemical (TSC)Textile chemicals are specialty chemicals used during the dyeing and processing of textiles to impart desired properties to the end-product. These products include coating and casing chemicals, colorants, auxiliaries, finishing agents, desizing agents and many more.
  • Animal health and nutrition (AHN) - Rossari manufactures over 100 products for its customers in this category which include poultry feed supplements and additives, pet grooming and pet treats including for weaning, infants and adult pets. 

Inorganic growth initiatives 

Rossari Biotech successfully acquired and integrated three companies in last 2 years- Unitop Chemicals Pvt Ltd (33% FY23 revenue share), Tristar Intermediates Pvt Ltd (13% FY23 revenue share) and Romakk Chemicals Pvt Ltd (2% FY23 revenue share).The strategic acquisition of Unitop has helped Rossari diversify its product portfolio with its expansive product range in the agrochemicals, anti-foams, hand gels, viscosity modifiers, marine cleaners and Anti-Stats segments. Tristar has brought in significant synergy to Rossari in Pharmaceuticals, Textiles, Paints, Automotive and Agro-chemicals segments. The focus of the acquisitions will be on cross-selling products to existing customers and expanding into new areas of specialty chemicals. 

In 2019, under the pet care segment, Rossari acquired a reputed Indian pet grooming brand - Lozalo International.      The product range includes natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquid. 

Competition 

  • In the HPPC segment major Indian companies producing active ingredients are Aarti Industries, Galaxy Surfactants and Atul. And in the institutional cleaning chemicals, some of their competitors are Diversey India, Schevaran Laboratories, Satol Chemicals, Ecolab India, Haylide Chemicals, Altret Industries, Croda India Company, and BASF India. Market is also characterized by strong presence of multinational companies such as Wacker AG, Merck and others.
  • Due to the large unbranded textile segment in India, the textile specialty chemical market in India is fragmented and largely unorganized and comprises a total of ~500 large and small manufacturers in India. In the organized textile specialty chemicals sector, some of Rossari’s competitors include Archroma, CHT, Rudolf, Croda international, Huntsman Corporation, Fineotex Chemical, Resil Chemicals, Sarex Chemicals, Dai-ichi Karkaria, Britacel Silicones, Indokem. 
  • In the animal health and nutrition products category, they compete with Cargill India, Zydus AH, a division of Cadila Healthcare, Bayer Animal Health, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Sequent Scientific, Elanco, Merial and Virbac.

While competition is present across categories, Rossari has created a place for itself on back of a) partnering with customers for solutions, b) long standing relationships, c) expertise in select sub-segments.

Positives and triggers 

  • HPPC segment growth
    • HPPC segment has grown at 56% CAGR over FY19-23 (including acquisitions). 
    • Ethoxylation is the property of providing cleaning, wetting, foaming and anti-foaming effects in personal care products such as cosmetics, shampoos, shower gels and detergents.
    • There have been capacity constraints in terms of Ethoxylation (current capacity -36,000 MTPA) which had capped growth. In Q2 FY24, the company proposed a capacity addition of 30,000 MTPA for Ethoxylation at its subsidiary Unitop Chemicals for a capex outlay of Rs.128 crores. 
    • Also, planned a capex of Rs.50 crores for adding 20,000 MTPA capacity at its Dahej Facility dedicated to products related to HPPC. These projects are expected to be commissioned in a phased manner till Q3 FY25. From this capex of about Rs.180 crores, company is expecting to generate incremental revenue of Rs.400 crores (~2.22 asset turnover; peak ~3.5x) or higher in the next 2-4 years. 
    • New product launches include green surfactants, performance chemicals, and biosurfactants in the HPPC segment. The company also plans to expand the manufacturing capacity of biosurfactants by 10 times from current capacity of 3 tons per month.
  • Export opportunity - Export turnover is expected to grow by a higher percentage than the domestic turnover which is ~14% CAGR. The company expects great upside for exports, especially in America in industries like home care, agro, food processing and surfactants for food processing. Launch of Ester Quartz (Softeners) which goes into commercial laundry as well as mainly into retail laundry seems to be a great candidate to bring growth in exports.  The emphasis is particularly strong on areas such as Specialty Surfactants, Phenoxy Series, Institutional Cleaning and Performance Chemicals. By leveraging the existing and new product lines, Rossari aims to penetrate deeper into new geographies and further increase the wallet share with existing partners.

Concern areas 

Client concentration risk and short term contract: Reliance on a limited number of customers for the business may generally involve several risks. Notably, the company does not have any long term agreements with most of their customers, and the loss of one or more of them or a reduction in the demand for their products could adversely affect the business. 

Raw Material Risk: Rossari’s largest expense is the cost of raw materials. Their primary raw materials are acrylic acid, surfactants and silicone oils which are subject to volatility due to factors beyond the company's control, such as market dynamics, economic conditions, and transportation and labor costs. The company does not have long-term agreements with suppliers, relying instead on purchaseorders, necessitating precise forecasting of supply and demand. Since product prices are typically fixed upon receiving a customer's purchase order, the company may not be able to fully transfer increased raw material costs to customers. But the same is done with some lag effect. 

Financials  

Revenues have more than tripled in the last 5 years from Rs.516 Cr. in FY19 to Rs.1656 Cr. in FY23 at a CAGR of 34%, majorly coming from the growth of HPPC segment. EBITDA has also shown consistent growth of 29% CAGR from FY19 to FY23. PAT has increased from Rs.46 Cr. in FY19 to Rs.107 Cr. in FY23 maintaining a moderate CAGR of 24% owing to increase in raw material costs. However, the raw material pressure has eased off over the last few quarters, which has led to an improvement in gross margins.

Management profile - Founders are technocrats with growth focus and clearly defined business roles. 

Mr. Edward Menezes - He is the Executive Chairman and guides the company's technical, manufacturing, and marketing strategies. He has a B.Sc. in Textile Chemistry from University Department of Chemical Technology (UDCT) and master’s degree in marketing management from Prin. L. N. Welingkar Institute of Management Development and Research. His career spans over 34 years in textile processing.

Mr. Sunil Chari- He is the Managing Director and brings over three decades of expertise in textiles and related chemicals. He has a Bachelor's in Arts from Kakatiya University and a diploma in technical and applied chemistry from Victoria Jubilee Technical Institute. He is the cornerstone of Rossari's formidable sales and distribution network, driving market expansion and financial fortitude.

Moneyworks4me Opinion- Rossari has low debt to equity ratio, industry leading asset turnover, and an experienced management team with a great execution track record. It is also a proxy play on FMCG sector wherein branded companies are relatively expensive. Future outlook is strong on a) expansion coming into play, b) entering new industries and increasing target addressable market, c) stable raw material prices. Only short term hindrance looks like muted FMCG volume growth (esp. rural volumes). We value Rossari at Rs.700 (18x forward PE for FY26) and will wait for a better entry price given that current risk reward scenario is not lucrative. 

Key Ratios of Rossari Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Tata Chemicals 812.4 -36.9 (-4.3%) Small Cap 15,421 -21.9 6.9 - 1
GNFC 492.1 -12.4 (-2.5%) Small Cap 7,930 34.2 6.2 14.8 0.9
Aarti Inds 374 -24.2 (-6.1%) Small Cap 6,372 10.1 6.6 39.3 2.6
Atul 5,400 -225.4 (-4%) Small Cap 4,358 137.7 8.5 40.8 2.9
Himadri Speciality 434.3 -22.4 (-4.9%) Small Cap 4,185 10.4 9.6 43.8 6.5
Jubilant Ingrevia 645.4 -27.5 (-4.1%) Small Cap 3,987 12.8 4.2 52.4 4.5
Chemplast Sanmar 428.9 -8 (-1.8%) Small Cap 3,923 -5.5 -3.8 - 38.5
Guj. Alkalies & Chem 627.1 -33 (-5%) Small Cap 3,807 -3.7 -3.5 - 0.7
GHCL 610.5 -11.3 (-1.8%) Small Cap 3,447 62.5 18 9.9 1.8
India Glycols 1,236.2 -20.8 (-1.7%) Small Cap 3,291 54.2 4.9 23.2 2.1
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales1711792332925166007091,4831,6561,831
Operating Expenses 1561662092474394955861,3071,4411,587
Manufacturing Costs4463131421384964
Material Costs1231311661973393724621,1081,1711,294
Employee Cost 111214202837426899103
Other Costs 1820232859736193123127
Operating Profit 1513244578105123176215243
Operating Profit Margin (%) 8.5%7.0%10.4%15.3%15.0%17.5%17.3%11.9%13.0%13.3%
Other Income 0011149191414
Interest 5421343132219
Depreciation 5545121723486360
Exceptional Items 0000000000
Profit Before Tax 5519406388107136144178
Tax 11311182327393747
Profit After Tax 43162946658098107131
PAT Margin (%) 2.2%1.9%6.7%9.9%8.8%10.9%11.3%6.6%6.5%7.1%
Adjusted EPS (₹)0.80.73.36.09.412.915.517.719.523.7
Dividend Payout Ratio (%)6%0%0%30%5%4%3%3%3%2%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 475065941242864078029121,044
Share Capital 444441010111111
Reserves 424661901192763967919011,033
Minority Interest0000000000
Debt39222220461006496
Long Term Debt9721134003533
Short Term Debt30152019327002963
Trade Payables1828324010697131186181219
Others Liabilities 1085114980107429415465
Total Liabilities 1141091241662835256451,4171,5721,825

Fixed Assets

Gross Block6738768886122234704743791
Accumulated Depreciation300384312295397158213
Net Fixed Assets383838457494181607585578
CWIP 78810322011647
Investments 00070180365163
Inventories31252435555895190188282
Trade Receivables303147608694144305354425
Cash Equivalents 13216127885212430
Others Assets755859112135225253399
Total Assets 1141091241662835256451,4171,5721,825

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 8267247157482915243
PBT 5519406388107136144178
Adjustment 9766172021558376
Changes in Working Capital -513-14-1111-31-48-112-28-157
Tax Paid -1-1-3-11-20-20-31-50-48-54
Cash Flow From Investing Activity -2-5-6-20-36-190-37-299-181-103
Capex -2-5-6-14-44-76-56-36-31-126
Net Investments 00007-1814-6-14-9
Others 000-71-965-257-13632
Cash Flow From Financing Activity -6-19-2-5-29157-252926116
Net Proceeds from Shares 000001004330244
Net Proceeds from Borrowing 0000-139-34045-12
Interest Paid -5-3-2-1-2-3-4-2-6-16
Dividend Paid 0000-11-3-3-3-3-3
Others -2-170-4-1624-27-52143
Net Cash Flow 020-2623-142232-44
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)8.186.9927.2736.3341.8831.8323.1116.1712.5213.36
ROCE (%)10.710.326.440.3754.437.9328.8124.3718.4818.39
Asset Turnover Ratio1.431.622.062.31.491.221.451.111.08
PAT to CFO Conversion(x)28.670.440.831.540.880.60.31.420.33
Working Capital Days
Receivable Days62626166515461557277
Inventory Days78583836323439354247
Payable Days686566677910090525756

Rossari Biotech Ltd Stock News

Rossari Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Rossari Biotech on 04-Apr-2025 10:14 is ₹618.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Apr-2025 10:14 the market cap of Rossari Biotech stood at ₹3,471.
The latest P/E ratio of Rossari Biotech as of 04-Apr-2025 10:14 is 31.98.
The latest P/B ratio of Rossari Biotech as of 04-Apr-2025 10:14 is 3.33.
The 52-week high of Rossari Biotech is ₹966.0 and the 52-week low is ₹568.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Rossari Biotech is ₹1,319 ( Cr.) .

About Rossari Biotech Ltd

The company was initially incorporated as Rossari Labtech on March 6, 2003, as a partnership firm under the Indian Partnership Act, 1932, pursuant to a certificate of registration dated June 22, 2003, issued by the Registrar of Firms, Mumbai. The name of the partnership firm was changed to Rossari Biotech on December 5, 2003 and further the firm converted into a joint stock company on August 10, 2009, under part IX of the Companies Act, 1956 as Rossari Biotech Limited with a certificate of incorporation granted by the Registrar of Companies, Maharashtra at Mumbai (RoC). The company received its certificate of commencement of business on August 13, 2009.

Business area of the company

The company is one of the leading specialty chemicals manufacturing companies in India providing customized solutions to specific industrial and production requirements of its customers primarily in the FMCG, apparel, poultry and animal feed industries through its diversified product portfolio comprising home, personal care and performance chemicals; textile specialty chemicals; and animal health and nutrition products. The company’s business is organized in three main product categories - (i) home, personal care and performance chemicals; (ii) textile specialty chemicals; and (iii) animal health and nutrition products.

The company is the leading manufacturer of acrylic polymers in India and manufactures many products for its customers in the soaps and detergent, paints, inks and coatings, ceramics and tiles, water treatment chemicals and pulp and paper industries. It also manufacture institutional cleaning chemical formulations for hospitality, facility management, airports, corporates, food service, commercial laundry, malls, multiplexes, educational sector, places of worship etc. It is in advanced stages of expanding its home, personal care and performance product portfolio to water treatment formulations, specialty formulation for breweries as well as dairies. Besides, the company provides specialty chemicals for the entire value-chain of the textile industry starting from fiber, yarn to fabric, wet processing and garment processing. The company has also diversified into animal health and nutrition and currently supply poultry feed supplements and additives, pet grooming and pet treats including for weaning, infants and adult pets.

Major Events & Milestones:

  • 2003: The company’s Promoters entered into a partnership firm to start the manufacturers of specialty chemicals and industrial enzymes in India.
  • 2004: Established first manufacturing facility at Silvassa.
  • 2009: Conversion of partnership firm into company.
  • 2009: Incorporation of company.
  • 2009: Obtained recognition for in-house R&D unit from the Department of Scientific and Industrial Research.
  • 2010: Forayed into animal health and nutrition products.
  • 2013: Forayed into HPPC products.
  • 2014: The company’s Promoters entered into a Joint Venture with BUZIL-WERK Wagner GmbH & Co. KG to form Buzil Rossari.
  • 2015: Lease granted by GIDC to company for setting up manufacturing facility at Dahej.
  • 2017: The Food Safety Management System of Silvassa Manufacturing Facility has been assessed and found to conform to the requirements of ISO 9001:2015.
  • 2018: Entered into an exclusive purchasing agreement with Hindustan Unilever.
  • 2020: Completion of the Pre-IPO Placement.

Awards & accreditations:

  • 2009: The erstwhile Hon’ble Union Finance Minister Pranab Mukherjee awarded ‘Corp EXCEL 2008– National mSME’ form a list of 27000 companies.
  • 2010: Frost & Sullivan awarded ‘Customer Value Enhancement for Industrial Enzymes Market’.
  • 2011: The Council for Fair Business Practices awarded ‘CFBP – Jamnalal Bajaj Uchit Vyavahar Puraskar for Fair Business Practices’.
  • 2017: The India SME Forum awarded at the India SME 100 Awards for ‘scoring in the top 100 in the overall evaluation of Financial & Non - Financial Parameters amongst 33102 nominations’.
  • 2018: Arvind awarded ‘Star Performer Award 2018’ in the Dye & Chemicals Category.
Read More Read Less
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...